Abstract
BackgroundIn order to define new prognostic subgroups in patients with glioblastoma a miRNA screen (> 1000 miRNAs) from paraffin tissues followed by a bio-mathematical analysis was performed.Methods35 glioblastoma patients treated between 7/2005 - 8/2008 at a single institution with surgery and postoperative radio(chemo)therapy were included in this retrospective analysis. For microarray analysis the febit biochip "Geniom® Biochip MPEA homo-sapiens" was used. Total RNA was isolated from FFPE tissue sections and 1100 different miRNAs were analyzed.ResultsIt was possible to define a distinct miRNA expression pattern allowing for a separation of distinct prognostic subgroups. The defined miRNA pattern was significantly associated with early death versus long-term survival (split at 450 days) (p = 0.01). The pattern and the prognostic power were both independent of the MGMT status.ConclusionsAt present, this is the first dataset defining a prognostic role of miRNA expression patterns in patients with glioblastoma. Having defined such a pattern, a prospective validation of this observation is required.
Highlights
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor [1]
Patient characteristics We examined paraffin tissue samples of a non-selected cohort of consecutively treated patients at the LudwigMaximilians university hospital Munich, Großhadern from 7/2005 to 8/2008
methylguanine DNA-methyltransferase (MGMT) status was available in 30 cases, missing in five cases
Summary
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor [1]. Concomitant and adjuvant administration of temozolomide improved 2-year survival of patients with newly diagnosed malignant glioma (mainly GBM) from 11% to 27%, 3-year survival from 4% to 16% and 5-year survival from 2% to 10% [3,4]. In addition to an improved application of radiotherapy, the combination of radiation with targeted drugs may turn out to increase the therapeutic ratio. In this regard different targeted molecules are currently undergoing pre-clinical and clinical testing [14,15,16,17,18,19,20]. In order to define new prognostic subgroups in patients with glioblastoma a miRNA screen (> 1000 miRNAs) from paraffin tissues followed by a bio-mathematical analysis was performed
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.